Strategic Collaborations OBT has a strong track record of multi-year partnerships with industry leaders such as Boehringer Ingelheim, Bristol Myers Squibb, Roche, and others, indicating a proven openness to external collaboration for asset discovery and development. This suggests sales opportunities in alliance formation, co-development, and licensing discussions to extend their IO and ADC programs.

Clinical Pipeline Momentum Lead asset OBT076 is advancing in Phase 1b with a dual mechanism that primes immune response while targeting cancer cells, signaling near-term advancement potential and a receptive window for partnership discussions around early-stage licensing, co-development, or strategic funding.

OGAP Platform Advantage OBT’s OGAP target discovery platform provides access to a large proprietary cancer membrane proteomic database and verified oncology targets, creating opportunities for platform licensing, target discovery collaborations, and expedited partner-driven program initiation.

Global Presence With operations and development activities in the UK and US (Oxford, San Jose, Morristown) and a network of partnerships across major biopharma, there is a clear global collaboration footprint suitable for international co-development, clinical trial support, and cross-border commercialization strategies.

Financial Footing Revenue in the tens of millions alongside a substantial funding runway positions OB T for continued R&D investments and strategic collaborations; potential sales targets include licensing deals, milestone-driven partnerships, and funded research arrangements to de-risk early-stage programs.